The new hires are Victor Lu, Ph.D., as senior vice president and head of Regulatory Affairs; Brad Fackler as senior vice president, Operations and Business Development; and Timothy Mitchell as vice president, Quality Assurance and Compliance.

“As we move toward our planned Phase I/II clinical trial initiation in lymphoma in 2019, we are excited to announce a significant U.S. presence out of our new offices in Maryland,” said Lei Xiao, Ph.D., chief executive officer of ICT. “The hiring of team members to oversee our regulatory, clinical, and operational functions here in the United States represents an important milestone for our global company, and we are extremely well-positioned to carry out our clinical development plans.”